A single-arm, multicenter, phase 2 study of camrelizumab in relapsed or refractory classical Hodgkin lymphoma.

CONCLUSIONS: Camrelizumab demonstrated high response rate, durable response and controllable safety in Chinese patients with relapsed or refractory cHL, becoming a new safe and effective treatment option in this setting.
PMID: 31420358 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - August 15, 2019 Category: Cancer & Oncology Authors: Song Y, Wu J, Chen X, Lin TY, Cao J, Liu YY, Zhao Y, Jin J, Huang H, Hu J, Luo J, Zhang L, Xue H, Zhang Q, Wang W, Chen CX, Feng J, Zhu J Tags: Clin Cancer Res Source Type: research